Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis.

Leukemia & Lymphoma
Mads Emil BjørnClaus Henrik Nielsen

Abstract

The role of excess reactive oxygen species (ROS) with consequent DNA/RNA damage is now recognized as a hallmark of cancer. In JAK2V617F mutated myeloproliferative neoplasms, ROS have been suggested to be important factors in disease initiation and progression. Ruxolitinib is the most widely used drug for myelofibrosis, because it improves symptom-score. However, both the anti-clonal potential and improvement in overall survival are limited. We investigated the impact of ruxolitinib on formation of superoxide radical and hydrogen peroxide by monocytes in sequentially acquired blood samples from patients with myelofibrosis. We also investigated the impact on RNA and DNA damage by measuring urinary excretion of 8-oxo-Guo and 8-oxo-d-Guo. The formation of superoxide by monocytes was reduced significantly during ruxolitinib therapy, but no impact on the formation of hydrogen peroxide by monocytes or the systemic amount of oxidatively damaged RNA or DNA could be demonstrated. We conclude that ruxolitinib holds little anti-oxidative potential.

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
May 27, 2009·Carcinogenesis·Francesco ColottaAlberto Mantovani
Jul 27, 2010·Experimental Hematology·Claudia VenerGiorgio Lambertenghi Deliliers
Feb 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ayalew TefferiAnimesh Pardanani
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Feb 19, 2013·Cytokine & Growth Factor Reviews·Hans C Hasselbalch
Sep 18, 2014·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·C ConradR Tirouvanziam
Apr 1, 2015·British Journal of Haematology·Sowmya Parampalli YajnanarayanaDominik Wolf
Apr 3, 2015·Cancer Research·Kathrin SchönbergDominik Wolf
Jun 2, 2015·Molecular Cell·Jian-Xun WangPei-Feng Li
Jun 16, 2015·British Journal of Haematology·Clodagh KeohaneGhulam J Mufti
Jun 19, 2015·British Journal of Haematology·Hanna JaniszewskaOlga Haus
Nov 6, 2015·Mediators of Inflammation·Sylvie HermouetBetty Gardie
Nov 6, 2015·Mediators of Inflammation·Mads Emil Bjørn, Hans Carl Hasselbalch
Nov 26, 2015·Mediators of Inflammation·Hans Carl Hasselbalch, Mads Emil Bjørn
Dec 8, 2015·Mediators of Inflammation·Christophe DesterkeMarie-Caroline Le Bousse-Kerdilès
Oct 21, 2016·Redox Biology·Sanne Tofte RasmussenHenrik Enghusen Poulsen

❮ Previous
Next ❯

Citations

Aug 31, 2019·British Journal of Haematology·Emanuela Sant'AntonioElisa Rumi
Sep 24, 2020·Hematology, Transfusion and Cell Therapy·Keli LimaJoão Agostinho Machado-Neto

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.